NCT05351684

Effect of Dolutegravir Intensification on HIV-1 Reservoirs

Effect of Dolutegravir Intensification on Blood and Tissue Latent HIV-1 Reservoirs and on Residual Viremia Despite ART

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: University of Liege · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Persistent HIV viremia occurs in most ART-treated patients and could arise from reactivation of viral expression from latently-infected cells that constitute the viral latent reservoir (LR) and/or residual ongoing viral replication during cART, for instance in anatomical compartment where drug penetration is sub-optimal. The question of the sources of persistent viremia is of the utmost importance. If ongoing viral replication occurs, it could induce deleterious consequences on reservoirs size and immune activation.We propose to better characterize the role ongoing viral replication to HIV persistence under ART by undertaking a treatment intensification trial with high-dose dolutegravir. Tissue/blood samples and replication-competent reservoir measurements will be included as outcomes as well as immune activation markers.

Conditions

• HIV-1-infection

Interventions

Type	Name	Description
DRUG	Dolutegravir 50 MG	already included in arm/group descriptions.

Timeline

• Start date: 2019-01-01
• Primary completion: 2022-08-28
• Completion: 2022-12-13
• First posted: 2022-04-28
• Last updated: 2022-12-15

Locations

1 site across 1 country: Belgium